REG - Scancell Hlds - Appointment of Sath Nirmalananthan to the Board

Scancell HoldingsAnnouncement

14/03/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240314:nRSN8935Ga&default-theme=true

RNS Number : 8935G  Scancell Holdings Plc  14 March 2024

14 March 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Appointment of Sath Nirmalananthan to the Board of Directors

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces that Sath
Nirmalananthan, Chief Financial Officer, has been appointed to the Company's
Board of Directors (the "Board") with immediate effect.

 

Sath was appointed as the Company's Chief Financial Officer on 29 August 2023,
having previously served as Chief Financial Officer for Europe, Middle-East
and Africa at Prenetics, a leading genomics-driven health sciences company. He
brings more than 15 years' experience in the healthcare sector, and has held
roles at FTSE and NASDAQ listed companies, including Reckitt and BTG. Prior to
this Sath held positions in investment banking at Nomura, and at KPMG. Sath is
a qualified Chartered Accountant and a member of the Institute of Chartered
Accountants in England and Wales (ICAEW), and sits as a Non-Executive member
of the audit committee at The Institute of Cancer Research (ICR). He was
awarded a BSc in Pharmacology from King's College, London.

 

Dr Jean-Michel Cosséry, Non-Executive Chairman of Scancell, commented: "Since
joining Scancell in August last year, Sath has brought considerable experience
and expertise to the role, overseeing our successful £12 million fundraise
from new and existing investors. Our focus remains on progressing SCIB1 and
Modi-1 through the clinic whilst also actively seeking out-licensing,
collaborations, and partnerships to accelerate the development and
commercialisation of our products and platforms. Working closely with the
Board, and Executive team, Sath will be instrumental in driving us towards
realising the potential of these treatments for patients, while creating and
delivering significant long-term value for our shareholders."

 

Commenting on his new appointment, Sath Nirmalananthan, Chief Financial
Officer and Director of Scancell, said: "I am proud to take on this expanded
role as a member of the Board, and I look forward to working with my fellow
Board members and the wider team to deliver our goals for 2024 and beyond.
This is an exciting time to be part of Scancell, as we continue to build
significant momentum and approach a number of important clinical milestones,
anticipated later this year, including further data from both the SCOPE and
ModiFY trials."

 

Additional Information

 

In accordance with the AIM Rules, the following information required to be
disclosed in relation to Sath Nirmalananthan is set out below. Other than this
information, there is no further information required to be disclosed under
paragraph (g) of Schedule Two of the AIM Rules.

 

Full name and age: Sathijeevan Nirmalananthan, aged 38

 

 Current Directorships  Previous Directorships (last 5 years)
 PNSN Company Limited   Oxsed Limited
                        DNA Fit Limited
                        DNA Sport Limited
                        DNAFIT Life Sciences Limited
                        Prenetics EMEA Limited
                        Prenetics Consumer Healthcare Limited
                        Duo Doc Limited
                        Norse Medica Limited
                        SP Care Holdings Limited

 

Mr Sath Nirmalananthan does not have an interest in any ordinary shares or
share options in Scancell.

 

 For further information, please contact:

 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330

 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                        +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                        scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQKQBDDBKDPND